Alexis Lara Rivero

Dear Editor, Immune checkpoint inhibitors (ICIs) have transformed the therapeutic landscape in oncology; however, cutaneous immune-related adverse events (cirAEs), affecting 30%–50% of patients [1], often complicate management. Lichenoid eruptions occur in approximately 6% of cirAEs and may lead to interruption or discontinuation of immunotherapy, potentially impacting prognosis.